DEGASPERI, MARGHERITA
 Distribuzione geografica
Continente #
NA - Nord America 163
EU - Europa 107
AS - Asia 69
AF - Africa 5
OC - Oceania 1
Totale 345
Nazione #
US - Stati Uniti d'America 161
CN - Cina 54
IT - Italia 44
FR - Francia 30
DE - Germania 8
NL - Olanda 6
VN - Vietnam 6
PL - Polonia 5
GB - Regno Unito 4
GH - Ghana 4
CZ - Repubblica Ceca 3
KR - Corea 3
AT - Austria 2
CA - Canada 2
JP - Giappone 2
AU - Australia 1
CH - Svizzera 1
ES - Italia 1
HK - Hong Kong 1
ID - Indonesia 1
MY - Malesia 1
NO - Norvegia 1
SE - Svezia 1
TH - Thailandia 1
UA - Ucraina 1
ZA - Sudafrica 1
Totale 345
Città #
Beijing 29
Trieste 20
Ashburn 16
Buffalo 12
Fleming Island 11
Fairfield 10
Woodbridge 9
Wilmington 7
Dong Ket 6
Santa Cruz 6
Seattle 6
Irvine 5
Paris 5
Accra 4
Boardman 4
Fremont 4
Hangzhou 4
Ann Arbor 3
Buk-gu 3
Houston 3
Las Vegas 3
Los Angeles 3
New York 3
Bologna 2
Bremen 2
Chicago 2
Clearwater 2
Council Bluffs 2
Frankfurt am Main 2
Herndon 2
Milpitas 2
Monfalcone 2
Portland 2
Qingdao 2
Rotterdam 2
Udine 2
Vienna 2
Warsaw 2
Washington 2
Amsterdam 1
Arzano 1
Assoro 1
Bari 1
Brooklyn 1
Changsha 1
Compiègne 1
Dallas 1
Decatur 1
Frankenau 1
Gontazaka 1
Guangzhou 1
Hackney 1
Henderson 1
Imbersago 1
Jacksonville 1
Lake Forest 1
Lublin 1
Mendham 1
Miami 1
Mountain View 1
Muizenberg 1
Nanjing 1
Naples 1
Nottingham 1
Ottawa 1
Padova 1
Parma 1
Perth 1
Phoenix 1
Pickering 1
Poznan 1
Provo 1
Puchong Batu Dua Belas 1
Rochester 1
Saint Cloud 1
San Francisco 1
San Severo 1
Santiago de Compostela 1
Sindelfingen 1
Starkville 1
Strasbourg 1
Tokyo 1
Venezia 1
Wroclaw 1
Zurich 1
Totale 254
Nome #
D-BMAP18 antimicrobial peptide is active In Vitro, resists to pulmonary proteases but loses its activity in a murine model of Pseudomonas aeruginosa lung infection, file e2913fdc-037e-f688-e053-3705fe0a67e0 109
Optimization of BMAP-18 an anti-infective peptide for the treatment of pulmonary infection, file e2913fde-74fb-f688-e053-3705fe0a67e0 63
In vitro and in vivo evaluation of BMAP-derived peptides for the treatment of cystic fibrosis-related pulmonary infections, file e2913fde-d85f-f688-e053-3705fe0a67e0 59
The anti-pseudomonal peptide d-bmap18 is active in cystic fibrosis sputum and displays anti-inflammatory in vitro activity, file e2913fde-001e-f688-e053-3705fe0a67e0 43
In vitro and in vivo evaluation of BMAP-derived peptides for the treatment of cystic fibrosis-related pulmonary infections, file e2913fde-d85e-f688-e053-3705fe0a67e0 29
D-BMAP18 antimicrobial peptide is active In Vitro, resists to pulmonary proteases but loses its activity in a murine model of Pseudomonas aeruginosa lung infection, file e2913fdc-0661-f688-e053-3705fe0a67e0 20
Elastase-Activated Antimicrobial Peptide for a Safer Pulmonary Treatment of Cystic Fibrosis Infections, file 8d52a499-45ad-4ddb-bbd2-c66be7cee6df 18
The anti-pseudomonal peptide d-bmap18 is active in cystic fibrosis sputum and displays anti-inflammatory in vitro activity, file e2913fde-1571-f688-e053-3705fe0a67e0 6
In vitro and in vivo evaluation of BMAP-derived peptides for the treatment of cystic fibrosis-related pulmonary infections, file e2913fde-699c-f688-e053-3705fe0a67e0 4
In vitro and in vivo evaluation of BMAP-derived peptides for the treatment of cystic fibrosis-related pulmonary infections, file e2913fdb-0d28-f688-e053-3705fe0a67e0 3
Totale 354
Categoria #
all - tutte 955
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 955


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/20197 0 0 0 0 0 0 0 0 3 1 2 1
2019/202031 2 2 1 6 3 3 2 3 4 2 2 1
2020/202125 2 1 1 0 3 2 2 0 4 6 1 3
2021/202247 2 2 16 6 2 3 1 0 2 3 8 2
2022/202393 1 5 9 8 18 3 15 5 2 9 13 5
2023/2024143 8 12 11 10 6 37 27 25 7 0 0 0
Totale 354